Evidence map›Paper›PMID 36709132›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia].

S Y Wang, L N Zhao, H Cheng, M Shi, W Chen, K M Qi, C Sun, X Wang, J Cao, K L Xu

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

S Y WangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
L N ZhaoDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
H ChengDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
M ShiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
W ChenDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
K M QiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
C SunDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
X WangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
J CaoDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
K L XuDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.
Xuzhou Medical College · CN

Funding

Xuzhou Medical Leading Talents Training Project XWRCHT20210028
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Precursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAcute DiseaseAntigens, CD19ChildHumansImmunotherapy, AdoptiveRecurrenceT-LymphocytesYoung AdultAntigens, CD19Receptors, Chimeric AntigenAcute lymphoblastic leukemiaCD19Chimeric Antigen ReceptorHumanizedRelapsed/refractory

Identifiers

PMID36709132
PMCPMC9395560
OpenAlexW4318450929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.